Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabazitaxel

FDA-approved product (solution, intravenous), marketed as Cabazitaxel, Jevtana Kit.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cabazitaxel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma
  • Prostate neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Taxanes
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabazitaxel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabazitaxel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

    NCT01757171 · start 2012-12

    Registered record
    Registry ID
    NCT01757171
    Conditions
    Gastric Adenocarcinoma; Gastroesophageal Adenocarcinoma; Distal Esophageal Adenocarcinoma
    Interventions
    Cabazitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-12
    Completion
    2017-06
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Adenocarcinoma; Gastroesophageal Adenocarcinoma; Distal Esophageal Adenocarcinoma
    InterventionCabazitaxel
    PhasePhase 2
    Registry statusCompleted

  • Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)

    NCT01830231 · start 2012-10

    Registered record
    Registry ID
    NCT01830231
    Conditions
    Urothelium Transitional Cell Carcinoma
    Interventions
    Cabazitaxel; Vinflunine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2012-10
    Completion
    2016-11
    Enrolment
    372

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelium Transitional Cell Carcinoma
    InterventionCabazitaxel; Vinflunine
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

    NCT01578655 · start 2012-08

    Registered record
    Registry ID
    NCT01578655
    Conditions
    Prostate Cancer
    Interventions
    cabazitaxel; prednisone; custirsen sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-08
    Completion
    2016-07
    Enrolment
    630

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventioncabazitaxel; prednisone; custirsen sodium
    PhasePhase 3
    Registry statusCompleted

  • Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

    NCT01505868 · start 2012-07-11

    Registered record
    Registry ID
    NCT01505868
    Conditions
    Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Lymphadenopathy; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Prostate Carcinoma Metastatic in the Bone; Prostate Small Cell Carcinoma
    Interventions
    Cabazitaxel; Carboplatin; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-07-11
    Completion
    2019-12-09
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Lymphadenopathy; Metastatic Prostate Carcinoma +3 more
    InterventionCabazitaxel; Carboplatin; Laboratory Biomarker Analysis
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

    NCT01469338 · start 2012-07

    Registered record
    Registry ID
    NCT01469338
    Conditions
    Diarrhea; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
    Interventions
    cabazitaxel; prednisone; octreotide pamoate; questionnaire administration; octreotide acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-07
    Completion
    2014-11
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiarrhea; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage I Prostate Cancer +4 more
    Interventioncabazitaxel; prednisone; octreotide pamoate; questionnaire administration +1 more
    PhasePhase 2
    Registry statusTerminated

  • Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

    NCT01649635 · start 2012-07

    Registered record
    Registry ID
    NCT01649635
    Conditions
    Prostate Cancer
    Interventions
    CABAZITAXEL (XRP6258); Prednisone; Ciprofloxacin; G-CSF (Granulocyte colony-stimulating factor)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-07
    Completion
    2016-06
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionCABAZITAXEL (XRP6258); Prednisone; Ciprofloxacin; G-CSF (Granulocyte colony-stimulating factor)
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment

    NCT01527929 · start 2012-04

    Registered record
    Registry ID
    NCT01527929
    Conditions
    Neoplasm Malignant
    Interventions
    Cabazitaxel XRP6258
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-04
    Completion
    2013-11
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasm Malignant
    InterventionCabazitaxel XRP6258
    PhasePhase 1
    Registry statusCompleted

  • Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

    NCT01528163 · start 2012-02

    Registered record
    Registry ID
    NCT01528163
    Conditions
    Squamous Cell Carcinoma of the Head and Neck
    Interventions
    Cabazitaxel; Methotrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-02
    Completion
    2014-11
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSquamous Cell Carcinoma of the Head and Neck
    InterventionCabazitaxel; Methotrexate
    PhasePhase 2
    Registry statusCompleted

  • The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

    NCT01513733 · start 2012-01

    Registered record
    Registry ID
    NCT01513733
    Conditions
    Prostate Cancer
    Interventions
    tasquinimod; tasquinimod 0.25 mg; 0.5 mg; tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-01
    Completion
    2016-06
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventiontasquinimod; tasquinimod 0.25 mg; 0.5 mg; tasquinimod 0.25 mg +2 more
    PhasePhase 1
    Registry statusCompleted

  • Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy

    NCT01497964 · start 2011-12

    Registered record
    Registry ID
    NCT01497964
    Conditions
    Gastric Cancer
    Interventions
    cabazitaxel XRP6258
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2011-12
    Completion
    2013-05
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer
    Interventioncabazitaxel XRP6258
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Second-line Chemotherapy in Castration Resistant Prostate Cancer

    NCT01558219 · start 2011-11

    Registered record
    Registry ID
    NCT01558219
    Conditions
    Metastatic Prostate Cancer
    Interventions
    cabacitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer
    Interventioncabacitaxel
    PhasePhase 2
    Registry statusCompleted

  • Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

    NCT01447225 · start 2011-10

    Registered record
    Registry ID
    NCT01447225
    Conditions
    Solid Tumors
    Interventions
    MM-121; Carboplatin; Pemetrexed; Cabazitaxel; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-10
    Completion
    2014-01
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionMM-121; Carboplatin; Pemetrexed; Cabazitaxel +1 more
    PhasePhase 1
    Registry statusCompleted

  • Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

    NCT01438307 · start 2011-09

    Registered record
    Registry ID
    NCT01438307
    Conditions
    Non-small Cell Lung Cancer (NSCLC); Stage IV NSCLC; Metastatic NSCLC
    Interventions
    Cabazitaxel-XRP6258 (3-week cycle); Cabazitaxel-XRP6258 (5-week cycle)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-09
    Completion
    2015-09
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer (NSCLC); Stage IV NSCLC; Metastatic NSCLC
    InterventionCabazitaxel-XRP6258 (3-week cycle); Cabazitaxel-XRP6258 (5-week cycle)
    PhasePhase 2
    Registry statusCompleted

  • Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

    NCT01308580 · start 2011-04

    Registered record
    Registry ID
    NCT01308580
    Conditions
    Prostate Cancer
    Interventions
    Cabazitaxel (XRP6258); Prednisone (or Prednisolone)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-04
    Completion
    2015-08
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionCabazitaxel (XRP6258); Prednisone (or Prednisolone)
    PhasePhase 3
    Registry statusCompleted

  • Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

    NCT01324583 · start 2011-01

    Registered record
    Registry ID
    NCT01324583
    Conditions
    Prostate Cancer
    Interventions
    Cabazitaxel (XRP6258); prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-01
    Completion
    2014-11
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionCabazitaxel (XRP6258); prednisolone
    PhasePhase 1
    Registry statusCompleted